No Data
No Data
Zhaoke Ophthalmology Grants 4.6 Million Share Options
Zhaoke Ophthalmology (HKG:6622) has granted 4,570,000 share options to 23 employees, directors and executive officers, a Wednesday filing on the Hong Kong bourse said. The options will allow the recip
Chaoke Ophthalmology - B (06622.HK) awards 4.57 million share purchase rights.
On July 3rd, Gelun Hui reported that Megain Medical Group Eye Department-B (06622.HK) has issued a total of 4.57 million share options to 23 grantees on July 3, 2024. The grantees are required to accept the options and comply with the listing rules and the terms of the share option plan after the initial public offering.
Zhaoke Ophthalmology Shrinks Loss in 2023
Zhaoke Ophthalmology (HKG:6622) recorded a decline in attributable loss for the year ended Dec. 31, 2023, to 385 million yuan from 407.3 million yuan in 2022, according to the company's annual report
ZHAOKE OPHTH-B: 2023 Annual Report
Zhaoke Ophthalmology-B (06622): Chen Yu resigns as non-executive director
Zhaoke Ophthalmology-B (06622) announced that Chen Yu has resigned as a non-executive director to spend more time on other work arrangements...
Annual Report Observation: The second low-concentration atropine produced in China is coming, and the value of Zhaoke Ophthalmology-B (6622.HK) has been rediscovered
The innovative ophthalmology drug market has always been one of the hot areas that the market has paid great attention to, especially in the field of myopic ophthalmology.
No Data